Eligible patients were aged @ years or older , with locally assessed HER@-positive advanced breast cancer , with Eastern Cooperative Oncology Group ( ECOG ) performance status of @-@ , who had not received previous trastuzumab or chemotherapy for advanced breast cancer within @ months of randomisation , had measurable disease as per Response Evaluation Criteria in Solid Tumors ( RECIST ) or bone lesions in the absence of measurable disease , without previous systemic treatment for advanced disease except endocrine therapy .